文献速递胸部肿瘤

纳武利尤单抗治疗经治晚期NSCLC的四年生存汇总分析

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
PubMed 文献 · Lancet Oncol · 2019-08-14

该汇总分析纳入四项纳武利尤单抗治疗经治晚期非小细胞肺癌(NSCLC)的临床研究(CheckMate 017、057、063、003),评估长期生存及缓解与疾病控制对后续生存的影响。全部患者4年总生存率为14%,PD-L1≥1%者为19%,PD-L1<1%者为11%;对比多西他赛的Ⅲ期研究中,纳武利尤单抗组4年总生存率为14%,多西他赛组为5%。6个月时缓解者的后续生存优于疾病进展者,长期数据未发现新的安全信号。

要点

  • 经治晚期NSCLC中,纳武利尤单抗4年总生存率14%,多西他赛为5%。
  • PD-L1≥1%者4年总生存率19%,PD-L1<1%者为11%。
  • 6个月时缓解者后续生存显著优于进展者,长期未见新安全信号。

核心结论

  • 纳武利尤单抗治疗经治晚期NSCLC的缓解持续时间长于多西他赛,并与长期生存获益相关。

研究设计与样本

  • 汇总四项纳武利尤单抗治疗经治NSCLC的临床研究(CheckMate 017、057、063、003),纳入二线及以上、随访至少4年的患者。
  • 纳武利尤单抗对比多西他赛的分析纳入Ⅲ期CheckMate 017和057的全部随机患者。
  • 按6个月时缓解状态做landmark分析以评估后续生存,排除6个月时无影像学肿瘤评估的患者。
  • 安全性分析纳入至少接受一剂纳武利尤单抗的全部患者。

主要发现

  • 四项研究合计664例患者,纳武利尤单抗4年总生存率为14%(95%CI 11–17)。
  • PD-L1表达≥1%者4年总生存率为19%(95%CI 15–24),PD-L1表达<1%者为11%(95%CI 7–16)。
  • CheckMate 017和057中,纳武利尤单抗组4年总生存率为14%(95%CI 11–18),多西他赛组为5%(95%CI 3–7)。

临床怎么用

  • 支持经治晚期NSCLC患者使用纳武利尤单抗可获得长期生存获益,6个月时达到缓解者后续生存预期更好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. METHODS: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 studies. We did landmark analyses by response status at 6 months to determine post-landmark survival outcomes. We excluded patients who did not have a radiographic tumour assessment at 6 months. Safety analyses included all patients who received at least one dose of nivolumab. FINDINGS: Across all four studies, 4-year overall survival with nivolumab was 14% (95% CI 11-17) for all patients (n=664), 19% (15-24) for those with at least 1% PD-L1 expression, and 11% (7-16) for those with less than 1% PD-L1 expression. In CheckMate 017 and 057, 4-year overall survival was 14% (95% CI 11-18) in patients treated with nivolumab, compared with 5% (3-7) in patients treated with docetaxel. Survival subsequent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for overall survival of 0·18 (95% 0·12-0·27) for nivolumab and 0·43 (0·29-0·65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0·52 (0·37-0·71) for nivolumab and 0·80 (0·61-1·04) for docetaxel. Long-term data did not show any new safety signals. INTERPRETATION: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage. FUNDING: Bristol-Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019. PMID: 31422028. doi:10.1016/S1470-2045(19)30407-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。